Multi-disciplinary approach to advance care and outcomes in patients with alcohol-associated liver disease (ALD) and alcohol use disorder (AUD)
Event
Date:
October 6, 2020 - 1:00 PM to October 6, 2020 - 4:00 PMDetails:
OBJECTIVES
- To enhance the understanding on the burden of alcohol use and alcohol-associated liver disease in the United States
- To enhance understanding of the concomitant mental health and substance use disorders among patients with alcohol use and alcohol-associated liver disease
- To bridge the clinical gaps in the alcohol-associated liver disease diagnosis, management and clinical trial design
- To disseminate the NIAAA-sponsored activities on clinical trials and translational research studies to advance the care and treatment of alcohol-associated liver disease to targeted audience
- To provide opportunities for graduate students and post-doctoral fellows to network with expert investigators in the area of alcohol use and alcohol-associated liver disease
ORGANIZERS
- Laura E. Nagy, PhD (nagyL3@ccf.org)
- Suthat Liangpunsakul, MD (sliangpu@iu.edu)
- Lorenzo Leggio, MD, PhD (lorenzo.leggio@nih.gov)
- Svetlana Radaeva, PhD (sradaeva@mail.nih.gov)
MEETING DETAILS
Tuesday, Oct 6, 2020 1:00 pm | 2 hours 30 minutes | (UTC-04:00) Eastern Time (US & Canada)
Meeting number: 126 760 8475
Password: grasshopper33
https://nih.webex.com/nih/j.php?MTID=ma668e7338fc7c6a4185b0847fb99f9a7
Join by phone
1-650-479-3208 Call-in toll number (US/Canada)
Access code: 126 760 8475
AGENDA
ZOOM session
Moderators: Laura E Nagy, PhD, Cleveland Clinic and Suthat Liangpunsakul, MD, Indiana University, IN
Format: 30 min per speaker (~22 min presentation and 8 min Q&A)
| 1:00pm |
Opening remarks
|
George Koob, PhD, NIAAA Director |
| 1:05pm |
Pathogenesis and mechanism of alcohol-associated liver disease – pave the way to therapeutic targets Inflammation or impaired regeneration: which pathways are important for treatment? |
Anna Mae Diehl, MD
|
| 1:35pm |
From bench to bedside - Disease Definitions and clinical studies AH Clinical trials in patients with AH – based on disease severity – inclusion and exclusion criteria, endpoints, duration, and confounders. |
Mack Mitchell, MD
|
| 2:05pm |
Clinical studies and the use of biomarkers in the real world, obstacles and challenge: Insights from the design and implementation of medications development trials for alcohol use disorder. |
Mark Thursz, MD
|
| 2:35pm
|
Clinical Addiction perspective – How to address AUD and substance abuse disorder in patients with alcohol-associated liver disease: behavioral and pharmacological intervention? |
Lorenzo Leggio, MD, PhD
|
| 3:05pm |
Liver transplantation in patients with alcohol-associated liver disease Preventing relapse after liver transplant: “app” based support. |
Betsy McCaul, PhD
|
Location:
Virtual Meeting